'CRISPR' Science: Newer Genome Editing Tool Shows Promise in Engineering Human Stem Cells

Contact Information

Available for logged-in reporters only

Newswise A powerful genome editing technology known as CRISPR has been used by researchers since 2012 to trim, disrupt, replace or add to sequences of an organisms DNA. Now, scientists at Johns Hopkins Medicine have shown that the system also precisely and efficiently alters human stem cells.

In a recent online report on the work in Molecular Therapy, the Johns Hopkins team says the findings could streamline and speed efforts to modify and tailor human-induced pluripotent stem cells (iPSCs) for use as treatments or in the development of model systems to study diseases and test drugs.

Stem cell technology is quickly advancing, and we think that the days when we can use iPSCs for human therapy arent that far away, says Zhaohui Ye, Ph.D., an instructor of medicine at the Johns Hopkins University School of Medicine. This is one of the first studies to detail the use of CRISPR in human iPSCs, showcasing its potential in these cells.

CRISPR originated from a microbial immune system that contains DNA segments known as clustered regularly interspaced short palindromic repeats. The engineered editing system makes use of an enzyme that nicks together DNA with a piece of small RNA that guides the tool to where researchers want to introduce cuts or other changes in the genome.

Previous research has shown that CRISPR can generate genomic changes or mutations through these interventions far more efficiently than other gene editing techniques, such as TALEN, short for transcription activator-like effector nuclease.

Despite CRISPRs advantages, a recent study suggested that it might also produce a large number of off-target effects in human cancer cell lines, specifically modification of genes that researchers didnt mean to change.

To see if this unwanted effect occurred in other human cell types, Ye; Linzhao Cheng, Ph.D., a professor of medicine and oncology in the Johns Hopkins University School of Medicine; and their colleagues pitted CRISPR against TALEN in human iPSCs, adult cells reprogrammed to act like embryonic stem cells. Human iPSCs have already shown enormous promise for treating and studying disease.

The researchers compared the ability of both genome editing systems to either cut out pieces of known genes in iPSCs or cut out a piece of these genes and replace it with another. As model genes, the researchers used JAK2, a gene that when mutated causes a bone marrow disorder known as polycythemia vera; SERPINA1, a gene that when mutated causes alpha1-antitrypsin deficiency, an inherited disorder that may cause lung and liver disease; and AAVS1, a gene thats been recently discovered to be a safe harbor in the human genome for inserting foreign genes.

Originally posted here:
'CRISPR' Science: Newer Genome Editing Tool Shows Promise in Engineering Human Stem Cells